RYTM Q3 2020 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$34M

Net Income

-$34M

EPS (Diluted)

$-0.77

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$215M

Total Liabilities

$19M

Stockholders' Equity

$197M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$34M	-$37M	+7.6%
Net Income	-$34M	-$36M	+6.1%